EFFECT OF ERBISOL ULTRApharm ON CELLULAR IMMUNITY CHARACTERISTICS IN PATIENTS WITH RECCURENT HERPES VIRUS INFECTION

  • A.I. Kurchenko MD, Prof.,Head of the Department of Clinical Immunology and Allergology with a section of Medical Genetics O.O.Bogomolets National Medical University
  • A.N. Nikolaenko D.Sc. in Biology, director SRC «Erbis»
  • G.V. Fedoruk MD, candidate of Medical Sciences, Associate Professor of the Department of Clinical Immunology and Allergology with a section of Medical Genetics O.O.Bogomolets National Medical University
  • A.E. Khaldieieva MD, post-graduate student of Medical Sciences of the Department of Clinical Immunology and Allergology with a section of Medical Genetics O.O.Bogomolets National Medical University
Keywords: frequently recurrent herpes, Erbisol® ULTRApharm, NK-cells, CD314, CD94, immunoadaptive effect

Abstract

The aim of the study was to detect the effect of Erbisol ULTRApharm on the cellular link of the immune system, thus estimating activating CD314 / NKG2D and
inhibiting CD94 / NKG2A receptors in patients with frequently recurrent herpes virus infection.
Material and methods of the study.A total of 15 patients with frequent herpes infection (with positive IFA and PCR tests as the selection criteria), with 5-6 exacerbation episodes a year, and 10 almost healthy people, without clinical manifestations of herpes infection, have been studied. All patients were administered the standard recommended therapy – Valacyclovir locally and Erbisol ULTRApharm intramuscularly, 1 ampoule i/m in the morning and evening during 12 days.
The peripheral blood subpopulation lymphocytes were detected by flow cytometry using reagents detecting clusters of differentiation of CD3, CD4, CD8, CD19, CD56, CD314(NKG2D) and CD94(NKG2A), produced by «Beckman Coulter Іnc.», USA. A flow cytometer NAVIOS («Beckman Coulter Іnc.») was used for cytofluorometric analysis.
Results. All patients, administered Erbisol ULTRApharm, were characterized by improved general health.
The clinical symptoms manifestations, represented with blisters and rash, decreased, with reduction of lesion area, pain and itching, compared to the previous
exacerbation. No relapses were detected during the subsequent 3-month observation. Modified expression of inducing and inhibiting receptors CD 314+ and
CD 94+ і on NK- і and Т-cytotoxic cells manifested inducing effect of the Erbisol ULTRApharm on T-cellular component of the immunity, and modification of quantity and relation of inducing NKG2D (CD314) and inhibiting CD94 / NKG receptors affected the immunoadaptive effect of the drug.
Conclusions. The drug Erbisol ULTRApharm, administered as a component of the treatment scheme for recurrent herpes infection, affects characteristics of expression of СD 314(NKG2D) and СD 94 (NKG2A or KIR) on natural killers and T-cytotoxic cells. The obtained dynamic results of modified characteristics of the cellular immunity evidence about activating effect of the drug, which makes a basis for the subsequent study of evidence-based mechanisms of interaction of T-cytotoxic and NK-cells under immune-dependent conditions, if the immunomodulating therapy includes the drug Erbisol-ULTRApharm.

Published
2021-11-28
How to Cite
Kurchenko, A., Nikolaenko, A., Fedoruk, G., & Khaldieieva, A. (2021). EFFECT OF ERBISOL ULTRApharm ON CELLULAR IMMUNITY CHARACTERISTICS IN PATIENTS WITH RECCURENT HERPES VIRUS INFECTION. Immunology and Allergy: Science and Practice, (3), 52-60. https://doi.org/10.37321/immunology.2021.3-06